BCRABL BREAKPOINT ANALYSIS,EDTA BLOODBONE MARROW

 No fasting or special preparation is required for this test. However, it is important to provide the clinician with a comprehensive medical history and prior treatment information to interpret the results effectively.

The BCR-ABL Breakpoint Analysis is a molecular diagnostic test used to identify specific fusion points between the BCR and ABL genes on chromosomes 22 and 9, respectively. This genetic rearrangement, also known as the Philadelphia chromosome, is a hallmark of certain types of leukemia, especially Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Pinpointing the exact breakpoint helps in monitoring disease progression, determining prognosis, and tailoring treatment strategies, particularly with tyrosine kinase inhibitors.

The test is performed using a blood or bone marrow sample. Molecular techniques such as reverse transcriptase-polymerase chain reaction (RT-PCR) or quantitative PCR are employed to detect and quantify the BCR-ABL fusion transcript. Some tests may also identify whether the fusion occurs at the major (M-BCR), minor (m-BCR), or micro (μ-BCR) breakpoint, which has implications for disease classification and therapy.

A positive result confirms the presence of a BCR-ABL fusion gene and supports the diagnosis of CML or Philadelphia chromosome-positive ALL. Monitoring changes in the levels of this gene over time can help assess treatment response or early signs of relapse. A declining or undetectable transcript level is generally a good prognostic sign, while persistent or increasing levels may indicate resistance or relapse.

Patients newly diagnosed with leukemia or those under treatment for CML or ALL are typically recommended to take this test. It is also used for ongoing monitoring during and after therapy to track minimal residual disease (MRD).